The efficacy and toxicity of combined therapy with irinotecan(CPT -11)plus mitomycin -C(MMC)were evaluated in patients with advanced or recurrent squamous cell carci-noma (SCC)of the uterine cervix.CPT -11(100mg /m 2 ...The efficacy and toxicity of combined therapy with irinotecan(CPT -11)plus mitomycin -C(MMC)were evaluated in patients with advanced or recurrent squamous cell carci-noma (SCC)of the uterine cervix.CPT -11(100mg /m 2 )was administered on days 1,8,and 15b y intravenous(iv)infusion over 90min,while MMC(10mg /m 2 iv)was given on day 1.This regimen was repeated every 28days and at least two courseswere given.A mong 51eligible patients(median age:52years;range:25-72years),2showed complete response(CR)and 24showed PR,for an overall response rate(ORR)of 51.0%(95%confidence interval:36.6-65.3%).In patients without prior chemotherapy,the ORR was 54.8%(38.7-70.2%).Twenty -five patients(Ib2:3,IIb:17,and IIIb:5)re-ceived this regimen as neoadjuvant c hemotherapy and their ORR was 76%(54.9-90.6%).Twentytwo patients were able to undergo radical surgery afte r NAC.The major tox-icity was neutropenia,which was gra de 3-4in 59%of the patients.Grade 3-4thrombocytopen ia and anemia were also seen in 26%of the patients each.The most common nonhematologic toxicitywas diarrh ea(grade 3-4in 12%).CPT -11combined with MMC can be effective against advanced or recurrent SCC of the uterine cervix.展开更多
文摘The efficacy and toxicity of combined therapy with irinotecan(CPT -11)plus mitomycin -C(MMC)were evaluated in patients with advanced or recurrent squamous cell carci-noma (SCC)of the uterine cervix.CPT -11(100mg /m 2 )was administered on days 1,8,and 15b y intravenous(iv)infusion over 90min,while MMC(10mg /m 2 iv)was given on day 1.This regimen was repeated every 28days and at least two courseswere given.A mong 51eligible patients(median age:52years;range:25-72years),2showed complete response(CR)and 24showed PR,for an overall response rate(ORR)of 51.0%(95%confidence interval:36.6-65.3%).In patients without prior chemotherapy,the ORR was 54.8%(38.7-70.2%).Twenty -five patients(Ib2:3,IIb:17,and IIIb:5)re-ceived this regimen as neoadjuvant c hemotherapy and their ORR was 76%(54.9-90.6%).Twentytwo patients were able to undergo radical surgery afte r NAC.The major tox-icity was neutropenia,which was gra de 3-4in 59%of the patients.Grade 3-4thrombocytopen ia and anemia were also seen in 26%of the patients each.The most common nonhematologic toxicitywas diarrh ea(grade 3-4in 12%).CPT -11combined with MMC can be effective against advanced or recurrent SCC of the uterine cervix.
